STOCK TITAN

Shuttle Pharma holders approve major share issuances

Shuttle Pharmaceuticals stockholders approved large merger- and financing-related share issuances, a major equity plan increase, and a name change to United Compute Inc.

(High)
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) reported that at a September 9, 2026 special meeting, stockholders approved several proposals authorizing substantial future issuances of common stock in connection with prior financing and merger-related transactions. As of the August 6, 2026 record date, 1,027,214 common shares were outstanding, and 588,987 shares, or 57.33%, were represented, constituting a quorum.

Stockholders approved, for purposes of Nasdaq Listing Rule 5635, multiple potential issuances tied to the Merger Agreement with United Dogecoin Inc., the Second Amendment to an Asset Purchase Agreement, and a Securities Purchase Agreement, including shares issuable upon conversion of Series B-1 and Series B-2 preferred stock and upon exercise of common stock purchase and pre-funded warrants. They also approved increasing the shares authorized under the 2018 Equity Incentive Plan to 8,800,000 and an amendment to change the company’s name to United Compute Inc. An adjournment proposal was also approved but ultimately not needed.

Positive

  • Stockholders approved key Nasdaq Listing Rule 5635 proposals enabling merger- and financing-related share issuances, reducing execution risk around the United Dogecoin Inc. and Securities Purchase Agreement transactions.
  • Approval to amend the 2018 Equity Incentive Plan increases authorized awards to 8,800,000 shares, giving the company more flexibility to use equity-based compensation.
  • Stockholders approved an amendment to change the company’s name to United Compute Inc., aligning the corporate identity with the strategic transactions described.

Negative

  • The approved proposals authorize the potential issuance of many millions of new shares (including via preferred stock conversions and warrant exercises) relative to 1,027,214 shares outstanding at the record date, implying significant potential dilution for existing common stockholders.

Insights

Analyzing...

Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Common shares outstanding at record date 1,027,214 shares Common stock outstanding as of August 6, 2026 record date
Shares represented at meeting 588,987 shares (57.33%) Shares present in person or by proxy at the September 9, 2026 special meeting
Series B-1 conversion shares (Merger Agreement) Up to 3,389,337 shares Common stock issuable upon conversion of Series B-1 Preferred under Merger Agreement
Pre-funded warrant exercise shares (Merger Agreement) Up to 12,292,752 shares Common stock issuable upon exercise of pre-funded warrants under Merger Agreement
Series B-2 conversion shares Up to 927,114 shares Common stock issuable upon conversion of Series B-2 Preferred under Securities Purchase Agreement
Series B-2 warrant exercise shares Up to 927,114 shares Common stock issuable upon exercise of common stock purchase warrants under Securities Purchase Agreement
Pre-funded warrant exercise shares (SPA) Up to 3,148,619 shares Common stock issuable upon exercise of pre-funded warrants under Securities Purchase Agreement
2018 Equity Incentive Plan authorization 8,800,000 shares Total common shares authorized for issuance under amended 2018 Equity Incentive Plan
Nasdaq Listing Rule 5635 regulatory
"To approve, for purposes of Nasdaq Listing Rule 5635, the issuance of"
Nasdaq Listing Rule 5635 is a stock-exchange rule that requires a listed company to get shareholder approval before issuing a large number of new shares or other securities that can convert into shares or carry voting power beyond set thresholds. Investors should care because these approvals prevent unexpected dilution of existing ownership and sudden shifts in voting control—think of it like needing agreement from current owners before cutting the pizza into many more slices that shrink each person’s piece.
pre-funded warrants financial
"pre-funded warrants and up to approximately 12,292,752 shares of Shuttle"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
Series B-1 Preferred Stock financial
"conversion of shares of Series B-1 Preferred Stock issued pursuant to"
Series B-2 Preferred Stock financial
"conversion of shares of Series B-2 Preferred Stock issued pursuant to"
Securities Purchase Agreement financial
"transactions contemplated by the Securities Purchase Agreement dated April 30, 2026"
A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.
Merger Agreement financial
"transactions contemplated by the Merger Agreement dated April 30, 2026"
A merger agreement is a binding contract that lays out the exact terms for two companies to combine, including the price, what each side will deliver, and the conditions that must be met before the deal is completed. Investors care because it sets the timetable, payouts and risks — like a blueprint or prenup that shows whether the deal is likely to close, how ownership will change, and what could cancel or alter the payout they expect.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did SHPH stockholders approve at the September 9, 2026 special meeting?

Stockholders approved multiple proposals under Nasdaq Listing Rule 5635 to allow substantial common stock issuances tied to preferred stock conversions and warrant exercises, an increase in the 2018 Equity Incentive Plan to 8,800,000 shares, and a name change to United Compute Inc.

How many SHPH shares were outstanding and represented at the record date for the meeting?

As of August 6, 2026, SHPH had 1,027,214 shares of common stock outstanding. At the special meeting, holders of 588,987 shares, or 57.33% of the outstanding shares, were represented in person or by proxy, constituting a quorum.

How did SHPH stockholders vote on the 2018 Equity Incentive Plan increase to 8,800,000 shares?

For the proposal to increase the 2018 Equity Incentive Plan authorization to 8,800,000 shares, there were 428,743 votes for, 25,023 against, 29 abstentions, and 135,192 broker non-votes. The proposal was approved by a majority of shares present and entitled to vote.

What were the voting results on SHPH’s name change to United Compute Inc.?

For the amendment to change the company’s name to United Compute Inc., there were 576,928 votes for, 10,868 against, and 1,191 abstentions, with no broker non-votes. Because a majority of outstanding shares was required, the proposal was approved.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
false 0001757499 0001757499 2026-09-09 2026-09-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of report (date of earliest event reported): September 9, 2026

 

SHUTTLE PHARMACEUTICALS HOLDINGS, INC.

 

(Exact name of registrant as specified in its charter)

 

Delaware   001-41488   82-5089826

(State or other jurisdiction

of incorporation)

 

Commission

File Number

 

(IRS Employer

Identification No.)

 

401 Professional Drive, Suite 260

Gaithersburg, MD 20879

(Address of principal executive offices) (Zip Code)

 

(240) 430-4212

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR

 

240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock $0.00001 per share   SHPH   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On September 9, 2026, Shuttle Pharmaceuticals Holdings, Inc. (the “Company”) held a Special Meeting of Stockholders (the “Meeting”).

 

As of August 6, 2026, the record date for the Meeting, 1,027,214 shares of the Company’s common stock, par value $0.00001 per share (“Common Stock”), were issued and outstanding, with each share entitled to one vote on each proposal at the Meeting. At the Meeting, the stockholders holding an aggregate of 588,987 shares of Common Stock entitled to vote at the Meeting were represented in person or by proxy, representing approximately 57.33% of the outstanding shares of Common Stock, and thereby a quorum was present for the Meeting.

 

The final results for each of the proposals considered at the Meeting are set forth below, as certified by the inspector of elections for the Meeting. These proposals are described in further detail in the Definitive Proxy Statement on Schedule 14A filed by the Company with the U.S. Securities and Exchange Commission on August 13, 2026, as supplemented (the “Proxy Statement”).

 

Proposal No. 1: To approve, for purposes of Nasdaq Listing Rule 5635, the issuance of (a) up to approximately 3,389,337 shares of Shuttle Common Stock in connection with the conversion of shares of Series B-1 Preferred Stock issued pursuant to the transactions contemplated by the Merger Agreement dated April 30, 2026 with United Dogecoin Inc. and described further in the Proxy Statement, (b) pre-funded warrants and up to approximately 12,292,752 shares of Shuttle Common Stock in connection with the exercise of such pre-funded warrants pursuant to the transactions contemplated by the Merger Agreement, (c) up to approximately 108,905 shares of Shuttle Common Stock in connection with the conversion of shares of Series B-1 Preferred Stock issued pursuant to the transactions contemplated by the Second Amendment to Asset Purchase Agreement as described further in the Proxy Statement, (d) pre-funded warrants and up to approximately 384,431 shares of Shuttle Common Stock in connection with the exercise of such pre-funded warrants pursuant to the transactions contemplated by the Second Amendment, (e) up to approximately 302,475 shares of Shuttle Common Stock in connection with the conversion of 750 shares of Series B-1 Preferred Stock issued and paid to E.F. Hutton & Co. as a financial advisory fee pursuant to the transactions contemplated by the Merger Agreement, and (f) pre-funded warrants and up to approximately 1,106,611 shares of Shuttle Common Stock in connection with the exercise of such pre-funded warrants to E.F. Hutton & Co. as a financial advisory fee pursuant to the transactions contemplated by the Merger Agreement.

 

For   Against   Abstentions   Broker Non-Votes
442,624   11,145   26   135,192

 

A majority of the shares present in person or by proxy and entitled to vote at the Meeting was required to approve Proposal No. 1 as provided above (“Proposal No. 1”). Accordingly, Proposal No. 1 was approved.

 

Proposal No. 2: To approve, for purposes of Nasdaq Listing Rule 5635, the issuance of (a) up to approximately 927,114 shares of Shuttle Common Stock in connection with the conversion of shares of Series B-2 Preferred Stock issued pursuant to the transactions contemplated by the Securities Purchase Agreement dated April 30, 2026 and described further in the Proxy Statement, (b) up to approximately 927,114 shares of Shuttle Common Stock in connection with the exercise of common stock purchase warrants issued pursuant to the transactions contemplated by the Securities Purchase Agreement and (c) pre-funded warrants and up to approximately 3,148,619 shares of Shuttle Common Stock in connection with the exercise of such pre-funded warrants pursuant to the transactions contemplated by the Securities Purchase Agreement.

 

For   Against   Abstentions   Broker Non-Votes
442,193   11,579   23   135,192

 

A majority of the shares present in person or by proxy and entitled to vote at the Meeting was required to approve Proposal No. 2 as provided above (“Proposal No. 2”). Accordingly, Proposal No. 2 was approved.

 

Proposal No. 3: To approve an amendment to the Company’s 2018 Equity Incentive Plan to increase the number of shares of Common Stock authorized for issuance thereunder to 8,800,000.

 

For   Against   Abstentions   Broker Non-Votes
428,743   25,023   29   135,192

 

A majority of the shares present in person or by proxy and entitled to vote at the Meeting was required to approve Proposal No. 3 as provided above (“Proposal No. 3”). Accordingly, Proposal No. 3 was approved.

 

Proposal No. 4: To approve an amendment to the Company’s Certificate of Incorporation to change the name of the Company to United Compute Inc.

 

For   Against   Abstentions   Broker Non-Votes
576,928   10,868   1,191   -

 

A majority of the outstanding shares of Common Stock was required to approve Proposal No. 4 as provided above (“Proposal No. 4”). Accordingly, Proposal No. 4 was approved.

 

Proposal No. 5: Approval of Adjournment of the Meeting

 

For   Against   Abstentions  

Broker Non-Votes

574,704   14,056   227   -

 

Although the proposal to adjourn the Meeting (“Proposal No. 5”) was deemed not necessary because there was a quorum present and there were sufficient votes at the time of the Meeting to approve all other proposals, a majority of shares present in person or by proxy and entitled to vote at the Meeting approved Proposal No. 5.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
     
104   Cover Page Interactive Data File (embedded within the inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: September 11, 2026

 

  SHUTTLE PHARMACEUTICALS HOLDINGS, INC.
     
By: /s/ Christopher Cooper
  Name: Christopher Cooper
  Title: Co-Chief Executive Officer

 

 

 

Filing Exhibits & Attachments

3 documents

Keep reading